Celsion Corp. (Nasdaq: CLSN) reported positive interim data from a Phase 2
DIGNITY Trial of ThermoDox to treat recurrent chest wall breast cancer. The stock price soared 63 cents to $3.29
Celsion reports positive interim data
April 15, 2015 at 12:43 PM EDT
